{
  "items": "29",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Precision Trading with Surrozen Inc. (SRZN) Risk Zones",
      "url": "https://news.stocktradersdaily.com/news_release/38/Precision_Trading_with_Surrozen_Inc._SRZN_Risk_Zones_122425060802_1766617682.html",
      "time_published": "20251224T180800",
      "authors": [
        "Randall S."
      ],
      "summary": "This article provides a detailed analysis of Surrozen Inc. (SRZN) for precision trading, leveraging AI-generated signals. It highlights strong sentiment supporting an overweight bias, outlines specific trading strategies including Position, Momentum Breakout, and Risk Hedging, and details multi-timeframe signal analysis with support and resistance levels. The analysis aims to optimize position sizing and minimize drawdown risk for traders.",
      "banner_image": "https://news.stocktradersdaily.com/media/693320_SRZN_graph.jpg",
      "source": "Stock Traders Daily",
      "category_within_source": "General",
      "source_domain": "Stock Traders Daily",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.934455"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.702568"
        }
      ],
      "overall_sentiment_score": 0.257574,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.267004",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Braidwell LP Buys Shares of 140,000 Surrozen, Inc. $SRZN",
      "url": "https://www.marketbeat.com/instant-alerts/filing-braidwell-lp-buys-shares-of-140000-surrozen-inc-srzn-2025-12-13/",
      "time_published": "20251213T180852",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Braidwell LP has acquired 140,000 shares of Surrozen, Inc. (NASDAQ:SRZN) for approximately $1.25 million, representing 1.64% of the company. Despite significant insider buying and a \"Moderate Buy\" consensus rating from analysts, Surrozen remains highly unprofitable. Several other institutional investors have also adjusted their holdings in the biotechnology company.",
      "banner_image": "https://www.marketbeat.com/logos/surrozen-inc-logo-1200x675.png?v=20211119084636",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.922247"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.815199"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.726979"
        }
      ],
      "overall_sentiment_score": 0.104973,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.103626",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Stempoint Capital LP Acquires 445,713 Shares of Surrozen, Inc. $SRZN",
      "url": "https://www.marketbeat.com/instant-alerts/filing-stempoint-capital-lp-acquires-445713-shares-of-surrozen-inc-srzn-2025-12-10/",
      "time_published": "20251210T180852",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Stempoint Capital LP significantly increased its stake in Surrozen, Inc. (NASDAQ:SRZN) by 185.1% in Q2, acquiring 445,713 additional shares. This move makes Surrozen the 20th-largest position in Stempoint's portfolio, despite the company having recently reported a large EPS miss and deep negative margins. Analysts currently rate Surrozen as a \"Moderate Buy\" with a consensus target price of $38.50.",
      "banner_image": "https://www.marketbeat.com/logos/surrozen-inc-logo-1200x675.png?v=20211119084636",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.933358"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.929520"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.832272"
        },
        {
          "topic": "finance",
          "relevance_score": "0.730485"
        }
      ],
      "overall_sentiment_score": 0.158476,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.169861",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Surrozen (NASDAQ:SRZN) Major Shareholder Buys $603,473.36 in Stock",
      "url": "https://www.marketbeat.com/instant-alerts/surrozen-nasdaqsrzn-major-shareholder-buys-60347336-in-stock-2025-12-08/",
      "time_published": "20251209T000912",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Group Gp Lp Column III, a major shareholder in Surrozen (NASDAQ:SRZN), acquired 30,884 shares for $603,473.36, increasing their direct ownership to 981,890 shares. Despite the company's unprofitability and negative margins, analysts maintain a \"Moderate Buy\" consensus. Institutional investors and hedge funds hold a significant 66.57% stake in the company.",
      "banner_image": "https://www.marketbeat.com/logos/surrozen-inc-logo-1200x675.png?v=20211119084636",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.946848"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.945782"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.848842"
        },
        {
          "topic": "finance",
          "relevance_score": "0.734976"
        }
      ],
      "overall_sentiment_score": 0.043895,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "0.344407",
          "ticker_sentiment_score": "0.036869",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Surrozen (NASDAQ:SRZN) Director Tim Kutzkey Purchases 30,884 Shares",
      "url": "https://www.marketbeat.com/instant-alerts/surrozen-nasdaqsrzn-director-tim-kutzkey-purchases-30884-shares-2025-12-08/",
      "time_published": "20251208T220912",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Surrozen (NASDAQ:SRZN) Director Tim Kutzkey purchased 30,884 shares of the company's stock on December 5th, totaling $603,473.36, bringing his total holdings to 981,890 shares. This transaction is part of a pattern of recent insider buying by Kutzkey, including significant purchases in November and early December. Despite recent losses, the company has a consensus \"Moderate Buy\" rating and a price target of $38.50 from analysts.",
      "banner_image": "https://www.marketbeat.com/logos/surrozen-inc-logo-1200x675.png?v=20211119084636",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.912940"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.826835"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.737274"
        }
      ],
      "overall_sentiment_score": -0.162046,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.124754",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Buys 5,266 Shares",
      "url": "https://www.marketbeat.com/instant-alerts/surrozen-nasdaqsrzn-major-shareholder-group-gp-lp-column-iii-buys-5266-shares-2025-12-08/",
      "time_published": "20251208T220912",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Group Gp Lp Column III, a major shareholder in Surrozen (NASDAQ:SRZN), recently purchased 5,266 shares on December 4th at $17.35 per share, adding to previous buys in November and December. These transactions increased their direct stake to 965,509 shares, representing a 0.55% ownership rise. Despite these acquisitions, Surrozen reported a weak quarter with an EPS of -$3.61 against an estimated -$1.17, yet analysts maintain a \"Moderate Buy\" rating with an average target price of $38.50.",
      "banner_image": "https://www.marketbeat.com/logos/surrozen-inc-logo-1200x675.png?v=20211119084636",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.922640"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.849601"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.721710"
        },
        {
          "topic": "finance",
          "relevance_score": "0.620478"
        }
      ],
      "overall_sentiment_score": 0.114943,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "0.970561",
          "ticker_sentiment_score": "0.122117",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Surrozen director Kutzkey purchases $3.99 million worth of company shares",
      "url": "https://meyka.com/blog/surrozen-director-kutzkey-purchases-3-99-million-worth-of-company-shares/",
      "time_published": "20251204T050149",
      "authors": [
        "Ayesha Sadeeqa"
      ],
      "summary": "Surrozen director Tim Kutzkey purchased $3.99 million worth of company shares on November 13, 2025, a move that signals confidence in the biotech firm's future, particularly its regenerative medicine pipeline. This significant insider buying, following a period of stock growth, suggests insiders believe the company is undervalued despite recent challenges like discontinued drug candidates and a terminated collaboration agreement. Surrozen focuses on Wnt-modulating antibodies to regenerate damaged tissues and recently secured a patent for its technology, reinforcing its long-term potential.",
      "banner_image": null,
      "source": "Meyka",
      "category_within_source": "General",
      "source_domain": "Meyka",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.930095"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.808858"
        }
      ],
      "overall_sentiment_score": 0.023138,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "0.305120",
          "ticker_sentiment_score": "0.042406",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tim Kutzkey Purchases 315,457 Shares of Surrozen (NASDAQ:SRZN) Stock",
      "url": "https://www.marketbeat.com/instant-alerts/tim-kutzkey-purchases-315457-shares-of-surrozen-nasdaqsrzn-stock-2025-12-02/",
      "time_published": "20251204T050149",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Tim Kutzkey, a director at Surrozen (NASDAQ:SRZN), recently acquired 315,457 shares for approximately $3.99 million, increasing his total stake to 962,718 shares. This transaction comes as Surrozen reported a significant quarterly EPS miss and negative margins, though analysts maintain a \"Moderate Buy\" rating with a consensus target price of $38.50. Hedge funds have also been adjusting their positions in the company.",
      "banner_image": "https://www.marketbeat.com/logos/surrozen-inc-logo-1200x675.png?v=20211119084636",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.935572"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.811986"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.741736"
        },
        {
          "topic": "finance",
          "relevance_score": "0.624932"
        }
      ],
      "overall_sentiment_score": 0.133897,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.129968",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Surrozen (NASDAQ:SRZN) Upgraded to \"Sell\" at Wall Street Zen",
      "url": "https://www.marketbeat.com/instant-alerts/surrozen-nasdaqsrzn-upgraded-to-sell-at-wall-street-zen-2025-11-29/",
      "time_published": "20251203T200905",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Wall Street Zen upgraded Surrozen (NASDAQ:SRZN) to a \"sell\" rating, despite a consensus \"Moderate Buy\" from other analysts. This comes after Surrozen reported a significant EPS miss and has negative net margins and return on equity. However, a major shareholder recently increased their position, and institutional investors also hold a significant portion of the company's stock.",
      "banner_image": "https://www.marketbeat.com/logos/surrozen-inc-logo-1200x675.png?v=20211119084636",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.933212"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.821918"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.904776"
        }
      ],
      "overall_sentiment_score": -0.212513,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.231361",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Surrozen director Kutzkey buys $3.99 million in SRZN stock By Investing.com",
      "url": "https://ng.investing.com/news/insider-trading-news/surrozen-director-kutzkey-buys-399-million-in-srzn-stock-93CH-2235710",
      "time_published": "20251203T200905",
      "authors": [
        "Investing.com"
      ],
      "summary": "Surrozen, Inc. director Tim Kutzkey reported purchasing $3.99 million worth of SRZN common stock on November 13, 2025, at $12.65 per share, below the current trading price. The purchases were made by The Column Group III, LP and The Column Group III-A, LP, increasing their collective holdings. Despite the company's \"FAIR\" financial health and cash burn, SRZN shares have seen an 85% return over six months, with analyst targets between $32 and $42.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_pile_69x52._800x533_L_1419494209.jpg",
      "source": "Investing.com Nigeria",
      "category_within_source": "General",
      "source_domain": "Investing.com Nigeria",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.946161"
        },
        {
          "topic": "finance",
          "relevance_score": "0.708017"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.649404"
        }
      ],
      "overall_sentiment_score": 0.308432,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.344364",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Surrozen director Kutzkey buys $3.99 million in SRZN stock",
      "url": "https://www.investing.com/news/insider-trading-news/surrozen-director-kutzkey-buys-399-million-in-srzn-stock-93CH-4387313",
      "time_published": "20251203T050149",
      "authors": [
        "Investing.com"
      ],
      "summary": "Surrozen director Tim Kutzkey purchased $3.99 million worth of SRZN common stock on November 13, 2025, at $12.65 per share, below the current trading price. The company's stock has seen an 85% return over the last six months, with analyst price targets between $32 and $42. Despite holding more cash than debt, Surrozen is burning through cash and has a \"FAIR\" financial health rating from InvestingPro.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_pile_69x52._800x533_L_1419494209.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.737147"
        },
        {
          "topic": "finance",
          "relevance_score": "0.633261"
        }
      ],
      "overall_sentiment_score": 0.027756,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "0.311327",
          "ticker_sentiment_score": "0.032610",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Surrozen (Nasdaq: SRZN) plans fireside talks at investor events, webcasts available",
      "url": "https://www.stocktitan.net/news/SRZN/surrozen-to-present-at-upcoming-healthcare-investor-gyfbuj2y6vjm.html",
      "time_published": "20251128T190919",
      "authors": [
        "NULL"
      ],
      "summary": "Surrozen (Nasdaq: SRZN) announced that its management will participate in two healthcare investor conferences in early December 2025: the 37th Annual Piper Sandler Healthcare Conference and the 8th Annual Evercore Healthcare Conference. The company will hold fireside discussions at both events, and investors can access live audio webcasts and replays through Surrozen's Investors website. The news of these presentations led to a moderate positive market reaction for SRZN stock, with a 2.72% gain on the day of the announcement.",
      "banner_image": "https://ml.globenewswire.com/media/M2Y5NDE3ZmEtY2JiMS00NjE3LTkwOWMtNmYwMGYwMjczZGE2LTEyMDc0ODYtMjAyNS0xMS0yNS1lbg==/tiny/Surrozen-Inc-.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.928315"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.730625"
        }
      ],
      "overall_sentiment_score": 0.187809,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.183341",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Surrozen to Present at Upcoming Healthcare Investor Conferences",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/SRZN-Q/pressreleases/36313753/surrozen-to-present-at-upcoming-healthcare-investor-conferences/",
      "time_published": "20251125T150500",
      "authors": [
        "NULL"
      ],
      "summary": "Surrozen, Inc. (Nasdaq: SRZN) announced that its management will participate in two upcoming healthcare investor conferences: the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025, and the 8th Annual Evercore Healthcare Conference on December 3, 2025. The biotechnology company, focused on Wnt pathway modulation for severe eye diseases, will provide audio webcasts of these presentations on its investor relations website for interested parties.",
      "banner_image": "NULL",
      "source": "The Globe and Mail",
      "category_within_source": "General",
      "source_domain": "The Globe and Mail",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.644175"
        }
      ],
      "overall_sentiment_score": 0.103914,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.109685",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Insider Buying: Surrozen (NASDAQ:SRZN) Major Shareholder Acquires 315,457 Shares of Stock",
      "url": "https://www.marketbeat.com/instant-alerts/insider-buying-surrozen-nasdaqsrzn-major-shareholder-acquires-315457-shares-of-stock-2025-11-17/",
      "time_published": "20251119T200905",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Group Gp Lp Column III, a major shareholder in Surrozen (NASDAQ:SRZN), acquired 315,457 shares for approximately $3.99 million on November 13, 2025, increasing its total holdings to 962,718 shares. This purchase represents a 48.74% increase in their ownership. Surrozen recently reported an EPS miss of ($3.61) and has a \"Moderate Buy\" consensus rating from analysts with an average target price of $38.50.",
      "banner_image": "https://www.marketbeat.com/logos/surrozen-inc-logo-1200x675.png?v=20211119084636",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.949492"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.825637"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.717544"
        }
      ],
      "overall_sentiment_score": -0.206798,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.223926",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Column group boosts Surrozen (SRZN) stake with $3.99 million purchase",
      "url": "https://www.investing.com/news/insider-trading-news/column-group-boosts-surrozen-srzn-stake-with-399-million-purchase-93CH-4363997",
      "time_published": "20251117T192000",
      "authors": [
        "Investing.com"
      ],
      "summary": "The Column Group entities recently boosted their stake in Surrozen Inc. (NASDAQ:SRZN) with a $3.99 million purchase of common stock. This insider buying occurred at $12.65 per share, slightly below the current trading price, following an 80% gain in the stock over the past six months. Despite institutional interest, Surrozen faces financial challenges including a negative EBITDA of -$37.23 million, though analysts project a potential upside with price targets ranging from $32 to $42.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.933323"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.841346"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.746741"
        }
      ],
      "overall_sentiment_score": 0.483737,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.485861",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Surrozen, Inc. Grants Inducement Stock Options to New CFO Andrew P. Maleki",
      "url": "https://www.quiverquant.com/news/Surrozen%2C+Inc.+Grants+Inducement+Stock+Options+to+New+CFO+Andrew+P.+Maleki",
      "time_published": "20251112T101100",
      "authors": [
        "NULL"
      ],
      "summary": "Surrozen, Inc. has granted 50,000 stock options to its new Chief Financial Officer, Andrew P. Maleki, as an inducement to accept his position. These options, approved under the company's 2025 Equity Inducement Plan, have an exercise price of $12.94 per share and will vest over four years. This move aims to strengthen Surrozen's leadership while adhering to Nasdaq regulations.",
      "banner_image": "NULL",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.932194"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.716145"
        },
        {
          "topic": "finance",
          "relevance_score": "0.641195"
        }
      ],
      "overall_sentiment_score": 0.107507,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.133480",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Surrozen, Inc. Reports Significant Q3 2025 Loss",
      "url": "https://www.tipranks.com/news/company-announcements/surrozen-inc-reports-significant-q3-2025-loss",
      "time_published": "20251110T050149",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Surrozen, Inc. reported a significant net loss of $71.6 million for Q3 2025, a substantial increase from a $1.4 million loss in the prior year, with revenue declining to $983,000. Despite these losses and rising operating expenses, the biotechnology company secured $71.2 million through a private placement to fund its ophthalmology programs. Management plans to use these funds to advance clinical studies and support its long-term business strategy.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2157214825-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.906996"
        }
      ],
      "overall_sentiment_score": -0.424953,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.400897",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "US Stock Market top gainers and losers on November 4: Surrozen, Inc sees 220% jump, Tradr 2X Long SRPT Daily ETF plunges by nearly 67%, NASDAQ, Dow Jones, S&P 500 end on lower side; here\u2019s how key indices performed - The Economic Times",
      "url": "https://m.economictimes.com/news/international/us/us-stock-market-top-gainers-and-losers-on-november-4-surrozen-inc-sees-220-jump-tradr-2x-long-srpt-daily-etf-plunges-by-nearly-67-nasdaq-dow-jones-sp-500-end-on-lower-side-heres-how-key-indices-performed/articleshow/125105823.cms",
      "time_published": "20251108T050149",
      "authors": [
        "Divyadeep Singh"
      ],
      "summary": "On November 4, 2025, the US stock market saw major indexes like the Dow Jones, S&P 500, and Nasdaq decline significantly due to warnings from bank CEOs about stretched valuations and geopolitical tensions. Surrozen, Inc. (SRZNW) was a top gainer, surging 220%, while Tradr 2X Long SRPT Daily ETF (SRPU) plunged by 66.22%. The tech sector was particularly hit, with six of the \"Magnificent Seven\" AI-related stocks losing ground.",
      "banner_image": "https://img.etimg.com/thumb/msid-125105819,width-650,height-488,imgsize-126704,resizemode-75/us-stock-market-top-gainers-and-losers-on-november-4.jpg",
      "source": "The Economic Times",
      "category_within_source": "General",
      "source_domain": "The Economic Times",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.821241"
        },
        {
          "topic": "economy_macro",
          "relevance_score": "0.746048"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.624169"
        }
      ],
      "overall_sentiment_score": -0.170699,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "0.344965",
          "ticker_sentiment_score": "0.015080",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PLTR",
          "relevance_score": "0.702249",
          "ticker_sentiment_score": "-0.235757",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "JPM",
          "relevance_score": "0.613669",
          "ticker_sentiment_score": "-0.216811",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Institutions along with private equity firms who hold considerable shares inSurrozen, Inc. (NASDAQ:SRZN) come under pressure; lose 13% of holdings value",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srzn/surrozen/news/institutions-along-with-private-equity-firms-who-hold-consid-30",
      "time_published": "20251108T050149",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Surrozen, Inc. (NASDAQ:SRZN) has a significant ownership structure where private equity firms hold 32% and institutions also hold 32% of the company. Recent market cap drops have put pressure on institutional investors, with private equity firms experiencing the most significant losses. The article delves into the various ownership groups, including hedge funds, the general public, and private companies, highlighting that the top 7 shareholders collectively own over half of the company's shares.",
      "banner_image": "NULL",
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.840786"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.739150"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.724220"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.617468"
        }
      ],
      "overall_sentiment_score": -0.373885,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.384245",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Surrozen, Inc. Reports Third Quarter 2025 Financial Results and Business Updates in Ophthalmology Pipeline",
      "url": "https://www.quiverquant.com/news/Surrozen%2C+Inc.+Reports+Third+Quarter+2025+Financial+Results+and+Business+Updates+in+Ophthalmology+Pipeline",
      "time_published": "20251107T211300",
      "authors": [
        "NULL"
      ],
      "summary": "Surrozen, Inc. announced its financial results for the third quarter of 2025, highlighting progress in its ophthalmology pipeline, particularly with lead candidate SZN-8141, for which an IND application is planned for 2026. The company reported a significant net loss of $71.6 million but maintained a cash position of $81.3 million as of September 30, 2025. Surrozen also strengthened its leadership team with the appointment of Andrew Maleki as Chief Financial Officer to drive growth and strategic initiatives.",
      "banner_image": "NULL",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.924879"
        }
      ],
      "overall_sentiment_score": -0.263403,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.256567",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Can Surrozen Inc. stock sustain institutional interest - Weekly Stock Analysis & Risk Controlled Stock Alerts",
      "url": "https://nchmf.gov.vn/video/Can-Surrozen-Inc.-stock-sustain-institutional-interest",
      "time_published": "20251021T163217",
      "authors": [],
      "summary": "The requested article content is unavailable due to a server error, specifically a \"404 - File or directory not found.\" This indicates that the resource for the article titled \"Can Surrozen Inc. stock sustain institutional interest\" cannot be located on the server. The content may have been removed, renamed, or is temporarily not accessible.",
      "banner_image": null,
      "source": "Trung t\u00e2m D\u1ef1 b\u00e1o KTTV qu\u1ed1c gia",
      "category_within_source": "General",
      "source_domain": "Trung t\u00e2m D\u1ef1 b\u00e1o KTTV qu\u1ed1c gia",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.547308"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.516179"
        }
      ],
      "overall_sentiment_score": 0.029678,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "0.303932",
          "ticker_sentiment_score": "0.017211",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Surrozen\u2019s Collaboration Agreement with TCGFB Terminated - TipRanks",
      "url": "https://www.tipranks.com/news/company-announcements/surrozens-collaboration-agreement-with-tcgfb-terminated",
      "time_published": "20251017T202933",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Surrozen announced the termination of its Collaboration Agreement with TCGFB, Inc., effective November 13, 2025. The termination, executed for convenience, incurs no penalties for either party and involved Surrozen providing antibody discovery services. This was a related party transaction due to shared affiliations, and Surrozen's stock is currently rated as a \"Buy\" by analysts with a $32.00 price target.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1096459574-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.927782"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.624408"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.528256"
        }
      ],
      "overall_sentiment_score": 0.029774,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "0.347249",
          "ticker_sentiment_score": "0.032250",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SRZN SEC Filings - Surrozen Inc 10-K, 10-Q, 8-K Forms - Stock Titan",
      "url": "https://www.stocktitan.net/sec-filings/SRZN/",
      "time_published": "20251017T201413",
      "authors": [],
      "summary": "This page provides a comprehensive resource for Surrozen Inc. (SRZN) SEC filings, including annual 10-K reports, quarterly 10-Q filings, 8-K material events, and insider trading forms. It highlights a recent 8-K filing from October 17, 2025, detailing the termination of a Collaboration Agreement between Surrozen and TCGFB, Inc., which involved antibody discovery services and intellectual property ownership. The article also provides real-time alerts and AI-powered summaries to help investors understand technical jargon and key financial details.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.941275"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.846555"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.518517"
        }
      ],
      "overall_sentiment_score": 0.016185,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "0.317721",
          "ticker_sentiment_score": "0.000238",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Surrozen, Inc. Receives Notice from TCGFB, Inc. to Terminate the Collaboration Agreement - MarketScreener",
      "url": "https://www.marketscreener.com/news/surrozen-inc-receives-notice-from-tcgfb-inc-to-terminate-the-collaboration-agreement-ce7d5addd18ff72c",
      "time_published": "20251017T201400",
      "authors": [
        "S&P Capital IQ"
      ],
      "summary": "Surrozen, Inc. announced that it received a notice from TCGFB, Inc. to terminate their Collaboration Agreement, effective November 13, 2025. TCGFB exercised its right to terminate for convenience, incurring no penalties for either party. Under the agreement, Surrozen provided antibody discovery services and was to receive up to $6.0 million along with a warrant for TCGFB common stock.",
      "banner_image": null,
      "source": "MarketScreener",
      "category_within_source": "General",
      "source_domain": "MarketScreener",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.919214"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.737893"
        }
      ],
      "overall_sentiment_score": 0.035936,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "0.349208",
          "ticker_sentiment_score": "0.013415",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Surrozen to Present at Upcoming Healthcare Investor Conference",
      "url": "https://investingnews.com/surrozen-to-present-at-upcoming-healthcare-investor-conference/",
      "time_published": "20250903T050149",
      "authors": [
        "Investing News Network"
      ],
      "summary": "Surrozen, Inc. (Nasdaq: SRZN) announced that its management will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025. The biotechnology company, which focuses on modulating the Wnt pathway for severe eye diseases, will hold its presentation from 8:30 \u2013 9:00 AM Pacific Time. Interested parties can access a webcast of the presentation via the Investors section of Surrozen's website.",
      "banner_image": "https://investingnews.com/media-library/image.gif?id=29654779&width=1200&height=1200",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.924361"
        },
        {
          "topic": "finance",
          "relevance_score": "0.742706"
        }
      ],
      "overall_sentiment_score": 0.147691,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.125489",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Surrozen, Inc. Prioritizes Ophthalmology Pipeline with $175 Million Financing and Discontinues SZN-043 Development",
      "url": "https://www.nasdaq.com/articles/surrozen-inc-prioritizes-ophthalmology-pipeline-175-million-financing-and-discontinues-szn",
      "time_published": "20250324T190919",
      "authors": [
        "None"
      ],
      "summary": "Surrozen, Inc. has announced a strategic shift to prioritize its ophthalmology pipeline, securing $175 million in financing to advance treatments for severe eye diseases while discontinuing the development of SZN-043 for alcohol-associated hepatitis due to inadequate early clinical benefit. The company's focus will now be on lead ophthalmology candidates SZN-8141 and SZN-8143, which are designed to address various retinal conditions and have shown promise in preclinical models. This financing is expected to fund these programs through early-phase clinical studies, with a collaboration also in place with Boehringer Ingelheim for SZN-413.",
      "banner_image": "NULL",
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.944940"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.800571"
        }
      ],
      "overall_sentiment_score": 0.441987,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.419430",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "The Column Group's biotech taps Surrozen for lung disease research pact",
      "url": "https://www.fiercebiotech.com/research/biotech-backed-column-group-taps-surrozen-target-tgf-beta-idiopathic-pulmonary-fibrosis",
      "time_published": "20241104T111400",
      "authors": [
        "Darren Incorvaia"
      ],
      "summary": "TCGFB, a private biotech funded by The Column Group, has partnered with Surrozen to discover antibodies for idiopathic pulmonary fibrosis, a devastating lung disease with no current cure. Surrozen will provide two years of antibody discovery services, focusing on targeting dysfunctional TGF-Beta, a key contributor to the disease. TCGFB is paying Surrozen up to $6 million for this research, aiming to develop a novel therapeutic approach.",
      "banner_image": null,
      "source": "Fierce Biotech",
      "category_within_source": "General",
      "source_domain": "Fierce Biotech",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.917768"
        }
      ],
      "overall_sentiment_score": -0.057055,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.301112",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.626914",
          "ticker_sentiment_score": "-0.423999",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration",
      "url": "https://www.stocktitan.net/news/SRZN/surrozen-earns-10-million-milestone-payment-in-retinal-diseases-j7bsiyga0c0j.html",
      "time_published": "20240924T083000",
      "authors": [],
      "summary": "Surrozen (Nasdaq: SRZN) announced a $10 million milestone payment from Boehringer Ingelheim as part of their collaboration on retinal diseases. Boehringer is advancing the development of SZN-413, a bi-specific antibody utilizing Surrozen's SWAP\u2122 technology, with the potential to restore retinal function in patients with retinal vascular diseases. Preclinical data suggests SZN-413 can stimulate Wnt signaling, induce normal retinal vessel regrowth, and suppress pathological vessel growth.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.929804"
        }
      ],
      "overall_sentiment_score": 0.401557,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.433120",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "A WNT mimetic with broad spectrum FZD-specificity decreases fibrosis and improves function in a pulmonary damage model",
      "url": "https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-024-02786-2",
      "time_published": "20240402T000000",
      "authors": [
        "Mehaben Patel",
        "Yorick Post",
        "Natalie Hill",
        "Asmiti Sura",
        "Jay Ye",
        "Trevor Fisher",
        "Nicholas Suen",
        "Mengrui Zhang",
        "Leona Cheng",
        "Ariel Pribluda",
        "Hui Chen",
        "Wen-Chen Yeh",
        "Yang Li",
        "H\u00e9l\u00e8ne Baribault",
        "Russell B. Fletcher"
      ],
      "summary": "A WNT mimetic with broad FZD-binding specificity (FZD1,2,5,7,8) effectively expanded alveolar organoids and, when therapeutically dosed, reduced pulmonary inflammation and fibrosis while improving lung function in an acute bleomycin model. This research indicates that modulating the Wnt/\u03b2-catenin pathway holds significant promise for treating pulmonary fibrosis, including conditions like Idiopathic Pulmonary Fibrosis (IPF). The findings suggest that transient activation of the Wnt/\u03b2-catenin pathway can effect tissue repair after lung damage.",
      "banner_image": null,
      "source": "Respiratory Research",
      "category_within_source": "General",
      "source_domain": "Respiratory Research",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.287695,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SRZN",
          "relevance_score": "0.909035",
          "ticker_sentiment_score": "0.406438",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.613635",
          "ticker_sentiment_score": "0.235073",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.631613",
          "ticker_sentiment_score": "0.214929",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.612774",
          "ticker_sentiment_score": "0.229997",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.636367",
          "ticker_sentiment_score": "0.234751",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    }
  ]
}